Table 43Botulinum toxin type A (Dysport) versus placebo Quality of life - Clinical study characteristics and clinical summary of findings

No. of studiesDesignTreatment (n)Control (n)ResultsLimitationsInconsistencyIndirectnessImprecisionOther considerationsQuality
Quality of life - Qualiveen
1 [A]RCTBotulinum toxin type A (Dysport)

N=17
Placebo

N=14
“Significant improvement seen on many quality of life parameters”
6 weeks (counts) Placebo slightly or not adversely affected 30 Extremely or not adversely affected 98 Treatment slightly or not adversely affected 176 Extremely or moderately affected 42
26 weeks (counts) Placebo slightly or not adversely affected 24 Extremely or not adversely affected 100 Treatment slightly or not adversely affected 148 Extremely or moderately 68
VS (i)NNN (ii)NLow

VS very serious N none

i

No details of randomisation or allocation concealment, incomplete outcome reporting

ii

Imprecision could not be assessed – no estimates of effect

[A]

Ehren et al. 200762

No details of randomisation or allocation concealment, incomplete outcome reporting

Imprecision could not be assessed – no estimates of effect

Ehren et al. 200762

From: 8, Treatment to improve bladder storage

Cover of Urinary Incontinence in Neurological Disease
Urinary Incontinence in Neurological Disease: Management of Lower Urinary Tract Dysfunction in Neurological Disease.
NICE Clinical Guidelines, No. 148.
National Clinical Guideline Centre (UK).
Copyright © 2012, National Clinical Guideline Centre.

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

The rights of National Clinical Guideline Centre to be identified as Author of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.